O	0	10	Prevention
O	11	13	of
B-condition	14	26	osteoporosis
O	27	29	as
O	30	31	a
O	32	43	consequence
O	44	46	of
O	47	56	aromatase
O	57	66	inhibitor
O	67	74	therapy
O	75	77	in
B-eligibility	78	92	postmenopausal
I-eligibility	93	98	women
I-eligibility	99	103	with
I-eligibility	104	109	early
I-eligibility	110	116	breast
I-eligibility	117	123	cancer
O	123	124	:
O	125	134	rationale
O	135	138	and
O	139	145	design
O	146	148	of
O	149	150	a
O	151	161	randomized
O	162	172	controlled
O	173	178	trial
O	178	179	.

O	180	189	Aromatase
O	190	200	inhibitors
O	201	202	(
O	202	205	AIs
O	205	206	)
O	207	211	have
O	212	220	improved
O	221	224	the
O	225	234	prognosis
O	235	238	for
O	239	245	breast
O	246	252	cancer
O	253	262	survivors
O	263	266	and
O	267	270	are
O	271	274	now
O	275	283	standard
O	284	286	of
O	287	291	care
O	292	295	for
O	296	310	postmenopausal
O	311	316	women
O	317	321	with
O	322	329	hormone
O	330	338	receptor
O	339	347	positive
O	348	353	early
O	354	359	stage
O	360	366	breast
O	367	373	cancer
O	373	374	.

O	375	378	One
O	379	383	side
O	383	384	-
O	384	390	effect
O	390	391	,
O	392	399	however
O	399	400	,
O	401	403	is
O	404	405	a
O	406	414	decrease
O	415	417	in
O	418	422	bone
O	423	430	mineral
O	431	438	density
O	439	440	(
O	440	443	BMD
O	443	444	)
O	445	448	and
O	449	458	increased
O	459	467	fracture
O	468	472	risk
O	472	473	.

O	474	479	Since
O	480	487	hormone
O	488	499	replacement
O	500	507	therapy
O	508	509	(
O	509	512	HRT
O	512	513	)
O	514	516	is
O	517	532	contraindicated
O	533	535	in
O	536	541	these
O	542	547	women
O	547	548	,
O	549	552	one
O	553	563	prevention
O	564	570	option
O	571	573	is
O	574	582	exercise
O	583	591	combined
O	592	596	with
O	597	604	vitamin
O	605	606	D
O	607	610	and
O	611	618	calcium
O	618	619	.

O	620	623	The
O	624	630	effect
O	631	633	of
O	634	638	this
O	639	651	intervention
O	652	654	on
O	655	659	drug
O	659	660	-
O	660	667	induced
O	668	680	osteoporosis
O	681	683	is
O	684	691	unknown
O	691	692	.

O	693	694	A
O	695	701	single
O	701	702	-
O	702	707	blind
O	708	718	randomized
O	719	729	controlled
O	730	735	trial
O	736	740	will
O	741	743	be
O	744	754	undertaken
O	755	757	to
O	758	762	test
O	763	766	the
O	767	777	hypothesis
O	778	782	that
B-intervention	783	791	exercise
I-intervention	792	800	combined
I-intervention	801	805	with
I-intervention	806	813	vitamin
I-intervention	814	815	D
I-intervention	816	819	and
I-intervention	820	827	calcium
O	828	831	can
O	832	839	prevent
O	840	843	the
O	844	852	decrease
O	853	855	in
O	856	859	BMD
O	860	870	associated
O	871	875	with
O	876	879	the
O	880	883	use
O	884	886	of
O	887	890	AIs
O	890	891	.

B-total-participants	892	897	Sixty
O	898	912	postmenopausal
O	913	918	women
O	919	929	prescribed
O	930	932	an
O	933	935	AI
O	936	939	for
O	940	943	the
O	944	953	treatment
O	954	956	of
O	957	963	breast
O	964	970	cancer
O	971	975	will
O	976	978	be
O	979	989	randomized
O	990	994	into
O	995	1001	either
O	1002	1004	an
O	1005	1013	exercise
O	1014	1016	or
B-control	1017	1024	control
I-control	1025	1030	group
O	1030	1031	.

O	1032	1044	Participants
O	1045	1055	randomized
O	1056	1058	to
O	1059	1062	the
O	1063	1071	exercise
O	1072	1077	group
O	1078	1082	will
O	1083	1092	undertake
O	1093	1094	a
O	1095	1097	12
O	1097	1098	-
O	1098	1103	month
O	1104	1107	gym
O	1107	1108	-
O	1108	1113	based
O	1114	1122	exercise
O	1123	1130	program
O	1130	1131	,
O	1132	1133	3
O	1134	1139	times
O	1140	1143	per
O	1144	1148	week
O	1149	1158	involving
O	1159	1169	resistance
O	1170	1173	and
O	1174	1180	impact
O	1181	1189	training
O	1189	1190	.

O	1191	1203	Participants
O	1204	1206	in
O	1207	1210	the
O	1211	1218	control
O	1219	1224	group
O	1225	1229	will
O	1230	1232	be
O	1233	1240	advised
O	1241	1243	on
O	1244	1247	the
O	1248	1256	benefits
O	1257	1259	of
O	1260	1268	exercise
O	1269	1272	for
O	1273	1283	preventing
O	1284	1296	osteoporosis
O	1296	1297	,
O	1298	1301	but
O	1302	1305	not
O	1306	1316	prescribed
O	1317	1325	exercise
O	1325	1326	.

O	1327	1331	Both
O	1332	1338	groups
O	1339	1343	will
O	1344	1351	receive
O	1352	1359	vitamin
O	1360	1361	D
O	1362	1365	and
O	1366	1373	calcium
O	1374	1385	supplements
O	1385	1386	.

O	1387	1390	The
O	1391	1398	primary
O	1399	1406	outcome
O	1407	1411	will
O	1412	1414	be
B-outcome-Measure	1415	1420	total
I-outcome-Measure	1421	1424	hip
I-outcome-Measure	1425	1429	bone
I-outcome-Measure	1430	1437	mineral
I-outcome-Measure	1438	1445	density
O	1446	1454	measured
O	1455	1458	via
O	1459	1463	dual
O	1464	1470	energy
O	1471	1472	X
O	1472	1473	-
O	1473	1476	ray
O	1477	1491	absorptiometry
O	1492	1493	(
O	1493	1496	DXA
O	1496	1497	)
O	1497	1498	.

O	1499	1504	Study
O	1505	1513	outcomes
O	1514	1518	will
O	1519	1521	be
O	1522	1530	compared
O	1531	1538	between
O	1539	1545	groups
O	1546	1548	at
O	1549	1557	baseline
O	1557	1558	,
O	1559	1566	6months
O	1567	1570	and
O	1571	1579	12months
O	1579	1580	.

O	1581	1585	This
O	1586	1591	study
O	1592	1596	will
O	1597	1608	investigate
O	1609	1612	the
O	1613	1619	effect
O	1620	1622	of
O	1623	1631	exercise
O	1632	1634	in
O	1635	1646	combination
O	1647	1651	with
O	1652	1659	vitamin
O	1660	1661	D
O	1662	1665	and
O	1666	1673	calcium
O	1674	1676	on
O	1677	1687	prevention
O	1688	1690	of
O	1691	1695	drug
O	1695	1696	-
O	1696	1703	induced
O	1704	1716	osteoporosis
O	1717	1719	in
O	1720	1734	postmenopausal
O	1735	1740	women
O	1741	1751	prescribed
O	1752	1755	AIs
O	1756	1759	for
O	1760	1763	the
O	1764	1773	treatment
O	1774	1776	of
O	1777	1783	breast
O	1784	1790	cancer
O	1790	1791	.
